Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model

(2012) Mitra Heravi et al.   ANTI-CANCER DRUGS

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

(2012) Y-C Shen et al.   BRITISH JOURNAL OF CANCER

Molecular mechanisms of sorafenib action in liver cancer cells

(2012) Melchiorre Cervello et al.   CELL CYCLE

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

(2012) William J. Gradishar et al.   EUROPEAN JOURNAL OF CANCER

Redox implications of AMPK-mediated signal transduction beyond energetic clues

(2012) S. Cardaci et al.   JOURNAL OF CELL SCIENCE

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

(2012) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib-Induced Mitochondrial Complex I Inactivation and Cell Death in Human Neuroblastoma Cells

(2012) Vibeke Hervik Bull et al.   JOURNAL OF PROTEOME RESEARCH

Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo

(2012) R. Coriat et al.   MOLECULAR CANCER THERAPEUTICS

AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: Implication of the cell survival in mitochondrial diseases

(2011) Shi-Bei Wu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism

(2011) Irene Sánchez-Hernández et al.   CANCER LETTERS

Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells

(2011) Luigi Fiume et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation

(2010) Wei Zhao et al.   ANTI-CANCER DRUGS

Synergistic activity of letrozole and sorafenib on breast cancer cells

(2010) Mara A. Bonelli et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

(2010) Claudine Isaacs et al.   BREAST CANCER RESEARCH AND TREATMENT

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

(2010) Giorgio Valabrega et al.   BREAST CANCER RESEARCH AND TREATMENT

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

(2010) D. Llobet et al.   EUROPEAN JOURNAL OF CANCER

Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization

(2010) Wenshan Hao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

(2009) Silvia La Monica et al.   BIOCHEMICAL PHARMACOLOGY

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

(2009) Hung Huynh et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

(2009) Paola Ulivi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

(2009) R. C. Kane et al.   ONCOLOGIST

Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer

(2008) Q. Ding et al.   CANCER RESEARCH

Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development

(2008) M. A. Tran et al.   CLINICAL CANCER RESEARCH

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells

(2008) Yvonne Will et al.   TOXICOLOGICAL SCIENCES